Abstract:NAD+ biosynthesis is an attractive and promising therapeutic target for influencing health span and obesity-related phenotypes as well as tumor growth. Full and effective use of this target for therapeutic benefit requires a complete understanding of NAD+ biosynthetic pathways. Here, we report a previously unrecognized role for a conserved phosphoribosyltransferase in NAD+ biosynthesis. Because a required quinolinic acid phosphoribosyltransferase (QPRTase) is not encoded in its genome, Caenorhabditis elegans are reported to lack a de novo NAD+ biosynthetic pathway. However, all the genes of the kynurenine pathway required for quinolinic acid (QA) production from tryptophan are present. Thus, we investigated the presence of de novo NAD+ biosynthesis in this organism. By combining isotope-tracing and genetic experiments, we have demonstrated the presence of an intact de novo biosynthesis pathway for NAD+ from tryptophan via QA, highlighting the functional conservation of this important biosynthetic activity. Supplementation with kynurenine pathway intermediates also boosted NAD+ levels and partially reversed NAD+-dependent phenotypes caused by mutation of pnc-1, which encodes a nicotinamidase required for NAD+ salvage biosynthesis, demonstrating contribution of de novo synthesis to NAD+ homeostasis. By investigating candidate phosphoribosyltransferase genes in the genome, we determined that the conserved uridine monophosphate phosphoribosyltransferase (UMPS), which acts in pyrimidine biosynthesis, is required for NAD+ biosynthesis in place of the missing QPRTase. We suggest that similar underground metabolic activity of UMPS may function in other organisms. This mechanism for NAD+ biosynthesis creates novel possibilities for manipulating NAD+ biosynthetic pathways, which is key for the future of therapeutics.

Cytoophidia: a conserved yet promising mode of enzyme regulation in nucleotide metabolism

Phospholipid Biosynthesis Modulates Nucleotide Metabolism and Reductive Capacity

Inositol Biosynthesis Is Fine-Tuned By Inositol Pyrophosphates In Saccharomyces Cerevisiae

A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis

Regulation of mammalian nucleotide metabolism and biosynthesis

Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle

De Novo Nucleotide Biosynthetic Pathway and Cancer

Cytoophidium complexes resonate with cell fates

Mitochondrial purine and pyrimidine metabolism and beyond

The Impact of Developmental and Metabolic Cues on Cytoophidium Formation

Modulation of Human UMP/CMP Kinase Affects Activation and Cellular Sensitivity of Deoxycytidine Analogs.

Modularized Reconstruction of Pyrimidine Pathway in Escherichia Coli for Enhanced Pyrimidine Nucleosides Biosynthesis

Kcs1 and Vip1: The Key Enzymes behind Inositol Pyrophosphate Signaling in Saccharomyces cerevisiae

De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence

Control of Glycolytic Flux in Directed Biosynthesis of Uridine-Phosphoryl Compounds Through the Manipulation of ATP Availability.

A new regulatory principle for in vivo biochemistry: pleiotropic low affinity regulation by the adenine nucleotides--illustrated for the glycolytic enzymes of Saccharomyces cerevisiae

Uridine monophosphate synthetase enables eukaryotic de novo NAD+ biosynthesis from quinolinic acid

Creating enzymes and self-sufficient cells for biosynthesis of the non-natural cofactor nicotinamide cytosine dinucleotide

Nanozyme‐Based Regulation of Cellular Metabolism and their Applications

A circuitous route for in vitro multi-enzyme cascade production of cytidine triphosphate to overcome the thermodynamic bottleneck

Structural basis of bifunctional CTP/dCTP synthase